CERP

Newly Published Phase II Clinical Study Demonstrates that Supplementation with Niagen®, Patented Nicotinamide Riboside (NR), Elevates NAD+ Up to Fourfold, Improving Motor Coordination and Eye Movement in Ataxia Telangiectasia (AT) Patients

Retrieved on: 
Wednesday, November 15, 2023

The promising results demonstrate that long-term supplementation with Niagen NR effectively increased whole blood NAD+ levels up to fourfold, improved coordination, and enhanced eye movement while maintaining biomarkers of stable liver and kidney function in Ataxia Telangiectasia (AT) patients.

Key Points: 
  • The promising results demonstrate that long-term supplementation with Niagen NR effectively increased whole blood NAD+ levels up to fourfold, improved coordination, and enhanced eye movement while maintaining biomarkers of stable liver and kidney function in Ataxia Telangiectasia (AT) patients.
  • AT is a rare, inherited neurodegenerative disorder characterized by premature aging, cerebellar degeneration, immunodeficiency, and cancer predisposition.
  • View the full release here: https://www.businesswire.com/news/home/20231115900463/en/
    Newly published phase II clinical study demonstrates that supplementation with Niagen, patented nicotinamide riboside (NR), elevates NAD+ up to fourfold, improving motor coordination and eye movement in Ataxia Telangiectasia (AT) patients (Graphic: Business Wire)
    Building on a growing body of research, this is the second published study ( Veenhuis et al.
  • This growing body of research is promising as it demonstrates that NR supplementation may be a potential therapeutic strategy for AT patients.”

UQAT to train all of its students in Indigenous perspectives by 2026

Retrieved on: 
Wednesday, December 6, 2023

This innovative initiative stems directly from the UQAT and Indigenous Peoples - Action Plan 2019-2024 and is one of several institutional actions of UQAT's Land acknowledgement principle.

Key Points: 
  • This innovative initiative stems directly from the UQAT and Indigenous Peoples - Action Plan 2019-2024 and is one of several institutional actions of UQAT's Land acknowledgement principle.
  • "Through this initiative, UQAT recognizes that Indigenous knowledge is just as important as scientific knowledge.
  • This recognition gives Indigenous perspectives a place in the programs offered at UQAT, thereby building on a plurality of knowledge", says Vincent Rousson, UQAT Rector.
  • A number of initiatives aimed at training students have already been in place for several years at UQAT.

ChromaDex, a Global Authority on Nicotinamide Adenine Dinucleotide (NAD+), Celebrates the 10th Anniversary of its ChromaDex External Research Program (CERP™), the Industry Leading Research Program Advancing the Science of NAD+ and Healthy Aging

Retrieved on: 
Friday, June 16, 2023

On June 13th, ChromaDex Corp. (NASDAQ:CDXC), a global authority on nicotinamide adenine dinucleotide (NAD+) research and healthy aging, celebrated the 10th anniversary of its award-winning ChromaDex External Research Program (CERP™).

Key Points: 
  • On June 13th, ChromaDex Corp. (NASDAQ:CDXC), a global authority on nicotinamide adenine dinucleotide (NAD+) research and healthy aging, celebrated the 10th anniversary of its award-winning ChromaDex External Research Program (CERP™).
  • On behalf of the ChromaDex family, we are thrilled to commemorate our ChromaDex External Research Program as it celebrates a decade of setting the industry standard for excellence in collaborative research,” said Rob Fried, the CEO of ChromaDex.
  • This approach fosters great trust in the research, as often there is skepticism around industry-funded research in the dietary supplement industry.
  • Today, this unique, industry-leading program has research agreements with over 200 institutions in 31 countries, representing over $95 million in estimated total research value.

Mindray To Host Renowned Critical Care Experts in Booth at NTI 2023

Retrieved on: 
Wednesday, May 10, 2023

MAHWAH, N.J., May 10, 2023 /PRNewswire-PRWeb/ -- Mindray, a global developer of technologies and solutions for patient monitoring, ultrasound, and anesthesia, today announced that they will be back again at the National Teaching Institute & Critical Care Exposition (NTI)2023 in Philadelphia, Pennsylvania to showcase its innovative solutions for advancing Critical Care and provide learning opportunities for attendees. Mindray invites all NTI attendees to visit Booth 1637 for live educational sessions led by well-known critical care expert Barbara McLean, MN, RN, CCRN, CCNS-BC, NP-BC, FCCM, and renowned clinical educator and speaker Nicole Kupchik, MN, RN, CCNS, CCRN, PCCN-K.

Key Points: 
  • Global developer of innovative healthcare solutions will attend NTI to showcase critical care solutions and host ExpoEd Sessions.
  • MAHWAH, N.J., May 10, 2023 /PRNewswire-PRWeb/ -- Mindray, a global developer of technologies and solutions for patient monitoring, ultrasound, and anesthesia, today announced that they will be back again at the National Teaching Institute & Critical Care Exposition (NTI) 2023 in Philadelphia, Pennsylvania to showcase its innovative solutions for advancing Critical Care and provide learning opportunities for attendees.
  • These Mindray-sponsored ExpoEd sessions are part of the NTI Critical Care Expo running May 23 – 24.
  • "Mindray is eager to host Barbara McLean and Nicole Kupchik in our booth at NTI this year," said Beth Aquaviva, Sr. Marketing Product Manager – Monitoring Solutions, Mindray North America.

Woolpert's David Wegner Appointed to Committee on Independent Scientific Review of Everglades Restoration Progress

Retrieved on: 
Monday, April 24, 2023

TUCSON, Ariz., April 24, 2023 /PRNewswire-PRWeb/ -- Woolpert Senior Strategic Consultant David Wegner has been appointed to the National Academies' Committee on Independent Scientific Review of Everglades Restoration Progress (CISREP). The CISREP was established in response to the Comprehensive Everglades Restoration Plan (CERP), a joint effort launched in 2000 as a federal-state partnership under the Water Resources Development Act with the objective to reverse the decline of the Everglades ecosystem in South Florida and restore the region's quantity, quality, timing, and delivery of water.

Key Points: 
  • Wegner will help evaluate the productivity and effectiveness of the Comprehensive Everglades Restoration Plan's current actions to restore and protect the region's water resources.
  • TUCSON, Ariz., April 24, 2023 /PRNewswire-PRWeb/ -- Woolpert Senior Strategic Consultant David Wegner has been appointed to the National Academies' Committee on Independent Scientific Review of Everglades Restoration Progress (CISREP).
  • The CISREP is a diverse team of science and ecology experts from universities across the country and the U.S. Environmental Protection Agency.
  • The committee will provide a biennial independent, peer-reviewed assessment that will detail overall progress made in restoring the Everglades ecosystem, significant accomplishments of the restoration progress thus far, and specific scientific and engineering issues that may impact progress in achieving the natural system restoration goals of the CERP.

ChromaDex Shares Promising Findings from First-Of-Its Kind Clinical Study to Demonstrate Oral Nicotinamide Riboside (NR) Supplementation Increases Muscle Mitochondrial Biogenesis

Retrieved on: 
Tuesday, January 17, 2023

Results of the study showcase that NR supplementation improved muscle mitochondrial biogenesis, satellite cell differentiation and gut microbiota composition.

Key Points: 
  • Results of the study showcase that NR supplementation improved muscle mitochondrial biogenesis, satellite cell differentiation and gut microbiota composition.
  • This is the first published and peer-reviewed clinical study demonstrating an increase in mitochondrial biogenesis following NR supplementation in humans and is consistent with a CERP preclinical study published in Cell Reports , demonstrating NR increased mitochondrial biogenesis in neuronal cells.
  • Additionally at five months, this clinical study marks a milestone as the longest published NR supplementation study to date.
  • “Our findings are a great advance in the field of muscle mitochondrial research, and they encourage us and others to continue to test the impact NR may have on muscle mitochondrial dysfunction,” Dr. Pirinen comments.

ChromaDex Reports FDA’s Conclusion that Nicotinamide Mononucleotide (NMN) May Not Be Sold or Marketed as a Dietary Supplement in the United States

Retrieved on: 
Friday, November 11, 2022

NMN cannot cross the cell membrane directly and must first be converted to nicotinamide riboside or NR, making NR a more efficient nicotinamide adenine dinucleotide (NAD+) precursor.

Key Points: 
  • NMN cannot cross the cell membrane directly and must first be converted to nicotinamide riboside or NR, making NR a more efficient nicotinamide adenine dinucleotide (NAD+) precursor.
  • Supplementation with Niagen is backed by over 20 published and peer-reviewed clinical trials, over 200 published scientific studies and over 40 owned and licensed patents.
  • The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age.
  • ChromaDex is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen.

ChromaDex’s Tru Niagen® Won the "Most Popular Brand of the Year Award" at China International Natural Health & Nutrition Expo’s (NHNE) Prestigious Nutrition Planet Awards

Retrieved on: 
Monday, October 24, 2022

Supplementation with Niagen is backed by 20 published and peer-reviewed clinical trials, over 200 published scientific studies and over 30 owned and licensed patents.

Key Points: 
  • Supplementation with Niagen is backed by 20 published and peer-reviewed clinical trials, over 200 published scientific studies and over 30 owned and licensed patents.
  • We are honored to bring such an excellent healthy-aging product to China, said Pan Lei, General Manager of Sinopharm Xingsha.
  • Tru Niagen has also been approved by Health Canada as a Natural Health Product.
  • Sinopharm Xingsha is the health supplement division of Sinopharm Group, a top 100 Chinese nutrition and health consumer brand enterprise, and a key pharmaceutical enterprise in Fujian Province, China.

ChromaDex Shares Promising Findings from Clinical Study Showcasing ​​the Safety and Tolerability of Nicotinamide Riboside (NR) in Heart Failure With Reduced Ejection Fraction

Retrieved on: 
Tuesday, October 4, 2022

The clinical study was part of the ChromaDex External Research Program (CERP) and investigated the safety and tolerability of the companys proprietary Niagen ingredient, patented nicotinamide riboside or NR, in Stage C heart failure patients with reduced ejection fraction (HFrEF), which occurs when the left ventricular ejection fraction (LVEF) is 40% or less.

Key Points: 
  • The clinical study was part of the ChromaDex External Research Program (CERP) and investigated the safety and tolerability of the companys proprietary Niagen ingredient, patented nicotinamide riboside or NR, in Stage C heart failure patients with reduced ejection fraction (HFrEF), which occurs when the left ventricular ejection fraction (LVEF) is 40% or less.
  • Heart failure is a clinical condition that is caused by structural and functional defects in the heart, which results in impaired filling or pumping of blood.
  • It offers a new therapeutic opportunity in heart failure and other conditions associated with chronic inflammation, said Dr. Rong Tian.
  • This randomized, double-blinded, placebo-controlled clinical study analyzed 30 Stage C heart failure patients over 12 weeks.

Parker Aerospace Engine-Driven Pump Selected by Boeing to Power the B-52H Stratofortress Hydraulic System for Decades

Retrieved on: 
Tuesday, September 20, 2022

Parker Aerospace , a business segment of Parker Hannifin Corporation, the global leader in motion and control technologies, today announced that Boeing selected Parker to supply its AP15V engine-driven pump (EDP) for the hydraulic system of the B-52H Stratofortress.

Key Points: 
  • Parker Aerospace , a business segment of Parker Hannifin Corporation, the global leader in motion and control technologies, today announced that Boeing selected Parker to supply its AP15V engine-driven pump (EDP) for the hydraulic system of the B-52H Stratofortress.
  • The Parker AP15V EDP, also known as the World Pump, will help power the aircrafts hydraulic system through the 2050s.
  • View the full release here: https://www.businesswire.com/news/home/20220919005191/en/
    Parker Aerospaces AP15V World Pump has been selected for the B-52 Stratofortress hydraulic system, helping the aircraft meet fuel efficiency and reliability goals for the Commercial Engine Replacement Program (CERP).
  • Parker Aerospace looks forward to supporting Rolls-Royce and Boeing in achieving these objectives and maximizing aircraft readiness.